NASDAQ: ALGS

Aligos Therapeutics Inc. (NASDAQ: ALGS), a San Francisco-based biotechnology company, has announced a clinical trial collaboration with Xiamen Amoytop Biotech Co., Ltd, a Chinese pharmaceutical firm. The partnership aims to explore the combination therapy of Aligos’ ALG-000184 with Amoytop’s Pegbing (mipeginterferon alfa-2b) for the treatment of chronic hepatitis B (CHB)…